Loading...

TENX TENAX THERAPEUTICS INC Company Mergers 8-K Filing

TNX

TNX

TENAX THERAPEUTICS INC

(TENX)

2025 8-K

Financial Results Announced

Management Change

Financial Results Announced

CMO Employment Update

Clinical Trial Update

Financial Results

Patent Grant Notification

License Agreement Update

Financial Results

Financial Statements

Financial Results

Private Placement

Management Change

Q3 Financial Results

Stock Plan Amendment

Q2 Financial Results

Private Placement

Annual Meeting and Director...

Financial Results Announcement

Financial Results Announcement

Compliance regained with Na...

Amendment to License Agreement

Public Offering

Enrollment in Phase 3 Study

Patent Allowed for Use of D...

Compliance Regained with Na...

Delisting Notice

Reverse Stock Split

Special Meeting of Stockhol...

FDA Clearance for IND Appli...

Bylaws Amendments

Annual Meeting Results

Patent Approval

Lease Termination

Public Offering

Patent Approval

Compliance with Nasdaq List...

Reverse Stock Split

External Links:

On September 3, 2025, Tenax Therapeutics, Inc. amended its License Agreement with Orion Corporation to gain exclusive rights to develop orally-administered products containing levosimendan, including pricing terms for supplies. The total price for levosimendan is in the low triple-digit thousands in Euros per kilogram.

AI Assistant

TENAX THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.